Mangoceuticals, Inc. has announced its combined 2025/2026 Annual Meeting of stockholders, set for December 30, 2026. This meeting is significant as it will address crucial proposals, including the election of board members and a potential reverse stock split.

The meeting will take place at 12 p.m. Central Time at the company’s office located at 17130 N. Dallas Parkway, Suite 240, Dallas, Texas. This event is particularly noteworthy as the company did not hold an annual meeting last year, making this gathering essential for shareholder engagement and governance.

Background

Mangoceuticals, Inc. operates within the Services-Misc Health & Allied Services, NEC (SIC 8090) sector. The company is listed on the Nasdaq under the ticker symbol MGRX. Recent filings include an 8-K and a preliminary proxy statement, with the latest filing dated November 6, 2026, under accession number 0001493152-26-050534.

What the Filing Says

The preliminary proxy statement details the agenda for the upcoming annual meeting, which includes:

  • Election of four members to the Board of Directors for a one-year term.
  • A proposal for a reverse stock split of the company’s outstanding common stock.
  • Approval of the Third Amendment to the Mangoceuticals, Inc. 2022 Equity Incentive Plan.

The board has nominated Jacob D. Cohen, Lorraine D’Alessio, Alex P. Hamilton, and Dr. Kenny Myers for re-election.

Impact

This meeting and the proposals put forth may significantly affect shareholders and the company’s operational strategies. The proposed reverse stock split could alter the share structure and market perception, while board elections will shape the company's governance moving forward.

What's Next

Following the annual meeting, stockholders will have the opportunity to vote on the proposals presented. The filing does not specify what happens next after the meeting.